On CNBC’s “The Final Call,” Carter Worth said he liked biotech. He named SPDR S&P Biotech ETF XBI hit a low on May 11 but “the S&P hasn’t bottomed yet.” “It’s up 32% since then,” he added.
Scott Nations said, “I want to use options to make money while defending my risk even if ExxonMobil Corp. XOM goes nowhere at all.”
Check out other stocks making moves in the premarket.
Mike Khouw said that he liked call spread risk reversals in SPDR S&P Biotech ETF. “For those of you who are thinking of trying to catch those falling knives, calls are a better way to play it.”
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.